Results 261 to 270 of about 112,374 (313)

Dapagliflozin for the treatment of heart failure with reduced ejection fraction in Brazil: a cost-effectiveness analysis. [PDF]

Lancet Reg Health Am
Naves MCX, Amato AA, Zimmermann IR, Peixoto HM.   +3 more
europepmc   +1 more source

Device therapies for heart failure with reduced ejection fraction: a new era. [PDF]

Front Cardiovasc Med
Mody R, Nee Sheth AB, Dash D, Mody B, Agrawal A, Monga IS, Rastogi L, Munjal A.   +7 more
europepmc   +1 more source

Early and rapid initiation of quadruple therapy for heart failure with reduced ejection fraction: A real-world experience. [PDF]

Clin Med (Lond)
Sze S, Thaitirarot C, Krishnan S, Chan D, Nicolson W, Squire I, Clayton L, Loke I.   +7 more
europepmc   +1 more source

Two causes of COVID‐19‐related myocardial injury‐associated cardiogenic shock: Myocarditis and microvascular thrombosis

ESC Heart Failure, Volume 12, Issue 2, Page 1514-1522, April 2025.
Takamasa Iwai, Hirohiko Aikawa, Yoshiaki Morita, Keiko Ohta‐Ogo, Teruo Noguchi   +4 more
wiley   +1 more source

Correction to 'Early experience of Sacubitril-Valsartan in heart failure with reduced ejection fraction in real-world clinical setting'. [PDF]

ESC Heart Fail
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Management of Heart Failure With Reduced Ejection Fraction

Current Problems in Cardiology, 2023
Heart failure with reduced ejection fraction (HFrEF) is a complex and progressive clinical condition characterized by dyspnea and functional impairment. HFrEF has a high burden of mortality and readmission rate making it one of the most significant public health challenges.
Ahmed Mustafa Rashid, Muhammad Shahzeb Khan, Marat Fudim, Tracy A. DeWald, Adam DeVore, Javed Butler   +5 more
openaire   +2 more sources